2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.
BioSpace8h
Can CB1 Inhibitors Make a Comeback in Obesity?
After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...
tyla31m
What Ozempic actually does to your body as numerous celebrities speak out about drug
More severe side effects can include pancreatitis, vision changes, allergic reactions, fatigue or dizziness, gallstones, ...
MedPage Today on MSN16hOpinion
'Physician Spending Is Not the Problem in Healthcare': What We Heard This Week
"It's very, very clear that physician spending is not the problem in healthcare." -- Jen Brull, MD, president of the American ...
Barchart on MSN7h
Here's What to Expect From DexCom's Next Earnings Report
With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous ...
Morningstar16h
Obesity Drug Market: The Next Wave of GLP-1 Competition
These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...
The Healthy on MSN21h
6 Foods To Eat on Semaglutides, Listed by a Doctor of Obesity Medicine
Nearly two-thirds (64%)  of Americans who have tried weight loss injections report the drugs as being “extremely effective” ...